Synthelabo Makes Acquisitions From Hoechst
Synthelabo of France is to make two acquisitions from the German Hoechst group. Synthelabo has signed an agreement to acquire from Hoechst the subsidiary Henning Berlin, which specializes in the treatment of thyroid disorders. In another agreement, Synthelabo is buying from Hoechst Marion Roussel the Strasbourg Research Center that belonged to Marion Merrell Dow.
Through the acquisition of Henning Berlin, Synthelabo hopes to achieve sales of over 1 billion French francs ($194.5 million) in Germany from 1997, and will hold a 1% stake in the German market. Henning achieved sales of 275 million francs in 1995, according to Synthelabo. The company said that Henning's products will complement its internal medicine range in Germany. Financial details of the deal were not disclosed.
Meantime, Synthelabo's acquisition of the Strasbourg Research Center from HMR covers all the teams specializing in structural sciences, molecular modelling, high-throughput screening and combinatorial chemistry, as well as corresponding facilities and equipment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze